3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
16
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Brain Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Gallbladder Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Clear Cell
1
Neoplasms, Unknown Primary
1
Microsatellite Unstable Colorectal Cancer
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Inflammatory Breast Neoplasms
1
Histiocytosis, Sinus
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Histiocytic Disorders, Malignant
1
Hematologic Neoplasms
1
Interventions
Gemcitabine
9
Carboplatin
8
Paclitaxel
6
Capecitabine
4
Bevacizumab
4
pembrolizumab
3
Irinotecan
3
Erlotinib Hydrochloride
3
atezolizumab
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Filgrastim
2
Cisplatin
2
CP protocol
2
tislelizumab
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
entrectinib
1
cobimetinib
1
belinostat
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Unknown Primary
×
cobimetinib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts